Skip to content

Scientific publications

  • article Freedman MS, Clift F, Devonshire V and Émond F, Larochelle C, Levin MC, MacLean H, Morrow SA, Prat A, Selchen D, Smyth P, Vorobeychik G

    First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus Recommendations

    Can J Neurol Sci 2025.

    DOI PUBMED
  • article Oh J, Bhan V, Traboulsee A, Morrow SA, Lee L, Levin M, Casserly C, Freedman MS, Giacomini PS and Émond F, Smyth P, Clift F, Selchen D

    Health Canada Drug Approval Process: A Barrier to Personalized Care in Multiple Sclerosis

    Can J Neurol Sci 2024.

    DOI PUBMED
  • article Bensaidane MR, Picher-Martel V and Émond F, De Serres G, Dupré N, Beauchemin P

    Case Report: Acute Necrotizing Encephalopathy Following COVID-19 Vaccine

    Front Neurol 13 2022.

    DOI PUBMED
  • article Cherkasova MV, Fu JF, Jarrett M, Johnson P, Abel S, Tam R, Rauscher A, Sossi V, Kolind S, Li DKB, Sadovnick AD, Machan L, Girard JM, Emond F, Vosoughi R, Traboulsee A, Stoessl AJ

    Cortical morphology predicts placebo response in multiple sclerosis

    Sci Rep 12 (1), 2022.

    DOI PUBMED
  • article Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, Laneuville P, Schecter R

    Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches

    Neural Regen Res 13 (11), 2018.

    DOI PUBMED
  • article Traboulsee AL, Machan L, Girard JM, Raymond J, Vosoughi R, Hardy BW, Emond F, Gariepy JL, Bone JN, Siskin G, Klass D, Isserow S, Illes J, Sadovnick AD, Li DK

    Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial

    Neurology 91 (18), 2018.

    DOI PUBMED
  • article Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, Laneuville P, Schecter R

    Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment

    Curr Med Res Opin 34 (8), 2018.

    DOI PUBMED
  • article Gamache PL, Gagnon MM, Savard M, Emond F

    Pulvinar sign in a case of anti-HU paraneoplastic encephalitis

    Neuroradiol J 29 (6), 2016.

    DOI PUBMED
  • article Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D, Lapierre Y and

    Treatment optimization in MS: Canadian MS Working Group updated recommendations

    Can J Neurol Sci 40 (3), 2013.

    DOI PUBMED
  • article Dupre N, Riviere JB, Myers RH, Provencher P, Pourcher E, Emond F, Rouleau GA

    LRRK2 is not a significant cause of Parkinson’s disease in French-Canadians

    Can J Neurol Sci 34 (3), 2007.

    DOI PUBMED